| View printer-friendly version|
|Dr. K. John Morrow, Jr., Noted Geneticist and Molecular Biologist, Joins Meridian Bioscience, Inc.|
|CINCINNATI, Feb 19, 2003 (BUSINESS WIRE) -- Meridian Bioscience, Inc.,
Cincinnati, Ohio (Nasdaq:VIVO) today announced that Dr. K. John Morrow, Jr. has
joined its expanding scientific team. Prior to Meridian, Dr. Morrow was
Professor of Cell Biology and Biochemistry at Texas Tech University Health
Sciences Center in Lubbock, Texas. Dr. Morrow's research expertise is in the
field of genetics and molecular systems for immunology. His current research is
in the area of genetically engineered antibodies, specifically for use in the
diagnosis and treatment of disease. He has authored more than fifty articles
published in referee journals, fifty-five review articles, and co-authored a
recent book, Antibody Engineering - Technologies, Applications, and Business
Opportunities, describing methods and theories of recombinant antibodies.
John A. Kraeutler, President and Chief Operating Officer, said, "The addition of
Dr. Morrow to our research teams at Meridian Bioscience, Viral Antigens, Inc.,
and BIODESIGN adds critical molecular capabilities and adds to our strategic
expansion into the biotechnology and early stage drug and vaccine development
Dr. Morrow said, "I look forward to applying my expertise and the power of
gene-based systems to further strengthen Meridian's capabilities in diagnostics,
as well as expanding biotechnology opportunities."
Meridian is a fully integrated life science company that manufactures, markets
and distributes a broad range of innovative diagnostic test kits, purified
reagents and related products and offers biopharmaceutical enabling
technologies. Utilizing a variety of methods, these products provide accuracy,
simplicity and speed in the early diagnosis and treatment of common medical
conditions, such as gastrointestinal, viral, urinary and respiratory infections.
All Meridian products are used outside of the human body and require little or
no special equipment. The Company's products are designed to enhance patient
well-being while reducing the total outcome costs of healthcare. Meridian has
strong market positions in the areas of gastrointestinal and upper respiratory
infections, serology, parasitology and fungal disease diagnosis. In addition,
Meridian is a supplier of rare reagents and specialty biologicals. The Company
markets its products to hospitals, reference laboratories, research centers,
veterinary testing centers and physician offices in more than 60 countries
around the world. The Company's shares are traded through Nasdaq's National
Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.
Meridian Bioscience, Inc.
John A. Kraeutler, 513/271-3700
Copyright (C) 2003 Business Wire. All rights reserved.